drugset / Trial / NCT04426708
A Clinical Study to Access the Pharmacokinetics of HMS5552 in Hepatic Impaired Subjects and Healthy Volunteers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objectives of this study is to access the pharmacokinetics and safety of HMS5552 in single dose in mild and moderate hepatic impaired subjects and matched healthy adult subjects.
Timeline
- Start
- 2019-02-18
- Primary completion
- 2020-07-03
- Completion
- 2020-07-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dorzagliatin | Small molecule | 25 mg | Oral |